| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000041221 |
| Receipt No. | R000047073 |
| Scientific Title | A study for the effect of the test food on fatigue caused by stress in daily life |
| Date of disclosure of the study information | 2020/07/31 |
| Last modified on | 2022/02/21 (Ver. 2) |
| Basic information | ||
| Public title | A study for the effect of the test food on fatigue caused by stress in daily life | |
| Acronym | A study for the effect of the test food on fatigue caused by stress in daily life | |
| Scientific Title | A study for the effect of the test food on fatigue caused by stress in daily life | |
| Scientific Title:Acronym | A study for the effect of the test food on fatigue caused by stress in daily life | |
| Region |
|
|
| Condition | |||
| Condition | Healthy volunteers | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To examine the effect of test food on fatigue caused by stress in daily life |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | -Fatigue sensation
-Autonomic nervous function |
| Key secondary outcomes | -Mood status
-Work performance -Cognitive function -Blood analysis |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake of test food for 4 weeks | |
| Interventions/Control_2 | Intake of placebo for 4 weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Males and females whose age of 20 years or more and less than 65 years
2)Subjects who answer the questionnaire that they have fatigue sensation in daily life 3)Subjects deemed fatigued based on their scores of VAS and Face scale at the screening 4)Subjects who work in the office 5)Subjects receiving a sufficient briefing of the objective and content of the present study, fully understanding and agreeing to voluntarily participate in the study and being able to personally sign a written informed consent |
|||
| Key exclusion criteria | 1)Subjects receiving a medical treatment for serious cardio-vascular, hepatic, renal, respiratory, endocrine or metabolic disorders or having a medical history of these disorders
2)Subjects having the chronic fatigue syndrome (CFS) , or subjects deemed to have severe fatigue such as idiopathic chronic fatigue by the investigator 3)Subjects who take regularly pharmaceuticals or quasi-drugs which having the efficacy for recovery from fatigue or nutritional supplements during physical fatigue 4)Subjects who take regularly Foods with Function Claims labeled the effect of attenuating fatigue sensation 5)Subjects who take regularly supplements of amino acids or proteins 6)Subjects who are heavy drinkers (>=60 g per day as pure alcohol) 7)BMI <18.5 kg/m2 and >=30 kg/m2 8)Subjects who have the possibility of primary diseases in autonomic nervous system 9)Subjects having blood sample of 200 ml or more taken within 1 month, or 400 ml or more within 3 months prior to the start of the present study (e.g. donated blood) 10)Subjects who took part in another clinical study within 3 months prior to the start of the present study or who is currently taking part in another clinical study 11)Female subjects who are pregnant or lactating, or intending to become pregnant during the study 12)Subjects deemed unsuitable by the investigator |
|||
| Target sample size | 48 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Ajinomoto Co., Inc. | ||||||
| Division name | Institute of Food Sciences and Technologies | ||||||
| Zip code | 2108681 | ||||||
| Address | 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa | ||||||
| TEL | 044-223-4114 | ||||||
| tomoyuki_mine@ajinomoto.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Ajinomoto Co., Inc. | ||||||
| Division name | Institute of Food Sciences and Technologies | ||||||
| Zip code | 2108681 | ||||||
| Address | 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa | ||||||
| TEL | 044-223-4114 | ||||||
| Homepage URL | |||||||
| daichi_shindo@ajinomoto.com | |||||||
| Sponsor | |
| Institute | Soiken Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Ajinomoto Co., Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | IRB of Fukuda Clinic |
| Address | Shin-Osaka brick building 2F, 1-6-1 Miyahara, Yodogawa-ku, Osaka-shi, Osaka |
| Tel | 06-6398-0203 |
| fukudaclinicIRB@gmail.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047073 |